ENROLLMENT STOPS; TWO-MONTH WAIT?
Regado anticoagulant's phase III clog: DSMB eyes allergic reaction threat
By Randy Osborne
Thursday, July 3, 2014
Regado Biosciences Inc.'s double-punch anticoagulant took one on the chin from Wall Street, as investors learned about an unplanned review by the data safety monitoring board (DSMB) of the phase III trial testing the drug previously known as REG1 in patients undergoing percutaneous coronary intervention (PCI).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.